Vol. 3 No. 12 (2023)
Reimbursement Recommendations

Mirikizumab (Omvoh)

Published December 4, 2023

Key Messages

  • CADTH recommends that Omvoh be reimbursed by public drug plans for the treatment of moderately to severely active ulcerative colitis (UC) if certain conditions are met.
  • Omvoh should only be covered for patients who are eligible for the reimbursement of other advanced drugs for the treatment of moderately to severely active UC (i.e., biologics and Janus kinase [JAK] inhibitors) based on the criteria used by each public drug plan.
  • Omvoh should only be reimbursed if prescribed by a physician experienced in the diagnosis and management of UC but should not be reimbursed if used in combination with biologic therapies or JAK inhibitors for UC. For ongoing treatment to keep UC under control, Omvoh should only be reimbursed if initial treatment reduces the severity of UC after 24 weeks. Patients should be reassessed every year for renewal. The cost of Omvoh should not exceed the drug program cost of treatment with the least costly biologic reimbursed for the treatment of UC.